JP2023540037A5 - - Google Patents
Info
- Publication number
- JP2023540037A5 JP2023540037A5 JP2023513355A JP2023513355A JP2023540037A5 JP 2023540037 A5 JP2023540037 A5 JP 2023540037A5 JP 2023513355 A JP2023513355 A JP 2023513355A JP 2023513355 A JP2023513355 A JP 2023513355A JP 2023540037 A5 JP2023540037 A5 JP 2023540037A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- item
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070707P | 2020-08-26 | 2020-08-26 | |
| US63/070,707 | 2020-08-26 | ||
| PCT/US2021/047757 WO2022047033A1 (en) | 2020-08-26 | 2021-08-26 | Antigen binding molecules targeting sars-cov-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540037A JP2023540037A (ja) | 2023-09-21 |
| JP2023540037A5 true JP2023540037A5 (enExample) | 2024-08-26 |
Family
ID=77897739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513355A Pending JP2023540037A (ja) | 2020-08-26 | 2021-08-26 | ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11987616B2 (enExample) |
| EP (1) | EP4204446A1 (enExample) |
| JP (1) | JP2023540037A (enExample) |
| KR (1) | KR20230058434A (enExample) |
| CN (1) | CN116528897A (enExample) |
| AU (1) | AU2021332340A1 (enExample) |
| CA (1) | CA3188716A1 (enExample) |
| IL (1) | IL300720A (enExample) |
| WO (1) | WO2022047033A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022010912A1 (en) | 2020-07-06 | 2022-01-13 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| CN116528897A (zh) | 2020-08-26 | 2023-08-01 | 旗舰开拓创新六世公司 | 靶向SARS-CoV-2的抗原结合分子 |
| AR123469A1 (es) * | 2020-09-10 | 2022-12-07 | Bighat Biosciences Inc | DOMINIOS DE UNIÓN A LA GLICOPROTEÍNA ESPICULAR DEL SARS-CoV(-2) Y POLIPÉPTIDOS QUE LOS COMPRENDEN Y USO DE ESTOS |
| EP4519310A1 (en) | 2022-05-06 | 2025-03-12 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
| WO2024102674A1 (en) | 2022-11-13 | 2024-05-16 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
| CN117442594A (zh) * | 2023-04-20 | 2024-01-26 | 厦门大学 | 化合物在诊断与治疗新型冠状病毒感染中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG128680A1 (en) | 2003-07-22 | 2007-01-30 | Crucell Holland Bv | Binding molecules against sars-coronavirus and uses thereof |
| CA2548942C (en) | 2003-12-05 | 2013-10-15 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Anti-sars monoclonal antibodies |
| US8106170B2 (en) | 2004-11-11 | 2012-01-31 | Crucell Holland B.V. | Compositions against SARS-coronavirus and uses thereof |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| HRP20150279T1 (hr) | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc inaäśice s promijenjenim vezanjem na fcrn |
| UA119328C2 (uk) | 2013-08-09 | 2019-06-10 | Астеллас Фарма Інк. | Антитіло до тslp-рецептора людини |
| CN108064243B (zh) | 2014-10-01 | 2021-08-27 | 免疫医疗有限公司 | 对lox1具有特异性的结合蛋白及其用途 |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| WO2020180398A1 (en) | 2019-01-14 | 2020-09-10 | The Regents Of The University Of California | Compositions and methods for modulating cellular internalization |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| JP2023512684A (ja) | 2020-02-03 | 2023-03-28 | ヴィア・バイオテクノロジー・インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法 |
| WO2021156490A2 (en) * | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
| BR112022017048A2 (pt) | 2020-02-26 | 2022-11-16 | Vir Biotechnology Inc | Anticorpos contra sars-cov-2 e métodos para usar os mesmos |
| EP4121454A1 (en) | 2020-03-19 | 2023-01-25 | Imperial College Innovations Limited | Coronavirus antibody |
| US11028167B1 (en) | 2020-03-23 | 2021-06-08 | Centivax, Inc. | Anti-SARS-Cov-2 antibodies derived from 3bgf |
| KR20250107297A (ko) | 2020-04-02 | 2025-07-11 | 리제너론 파아마슈티컬스, 인크. | 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편 |
| WO2021203053A1 (en) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
| US20230348571A1 (en) | 2020-04-06 | 2023-11-02 | Vanderbilt University | Cross-reactive coronavirus antibodies and uses thereof |
| JP2023521418A (ja) | 2020-04-10 | 2023-05-24 | インビビド， インコーポレイテッド | コロナウイルスｓタンパク質に特異的な化合物及びその使用 |
| US20240059757A1 (en) | 2020-04-14 | 2024-02-22 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
| US20230174628A1 (en) | 2020-04-28 | 2023-06-08 | Peking University | Anti-novel coronavirus monoclonal antibody and application thereof |
| WO2021226560A1 (en) | 2020-05-08 | 2021-11-11 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 |
| WO2021247925A1 (en) | 2020-06-03 | 2021-12-09 | Vir Biotechnology, Inc. | Structure-guided immunotherapy against sars-cov-2 |
| WO2022010912A1 (en) | 2020-07-06 | 2022-01-13 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| WO2022015573A2 (en) | 2020-07-13 | 2022-01-20 | President And Fellows Of Harvard College | Sars-cov-2 antigen-binding proteins and uses thereof |
| WO2022026475A2 (en) | 2020-07-27 | 2022-02-03 | Igm Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| WO2022046888A1 (en) | 2020-08-25 | 2022-03-03 | Target Discovery Merger Sub II, LLC | Sars-cov-2 associated antibody compositions and methods of use |
| CN116528897A (zh) | 2020-08-26 | 2023-08-01 | 旗舰开拓创新六世公司 | 靶向SARS-CoV-2的抗原结合分子 |
| KR20230127305A (ko) | 2020-12-29 | 2023-08-31 | 발-첨, 리미티드 파트너십 | Covid-19에 대한 중화 단일클론 항체 |
| WO2022159685A2 (en) | 2021-01-22 | 2022-07-28 | Vanderbilt University | Sars-cov-2 coronavirus antibodies and uses thereof |
| WO2022204202A1 (en) | 2021-03-23 | 2022-09-29 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| KR20240035758A (ko) | 2021-05-24 | 2024-03-18 | 비르 바이오테크놀로지, 인코포레이티드 | 조작된 폴리펩타이드 |
| WO2022271863A1 (en) | 2021-06-23 | 2022-12-29 | Chan Zuckerberg Biohub, Inc. | Coronavirus neutralizing compositions and associated methods |
| WO2023028603A2 (en) | 2021-08-27 | 2023-03-02 | Humabs Biomed Sa | Engineered compositions |
| EP4147716A1 (en) | 2021-09-10 | 2023-03-15 | Samatva Research Corporation | Anti-virus moiety immobilised in a matrix |
| EP4519310A1 (en) | 2022-05-06 | 2025-03-12 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
-
2021
- 2021-08-26 CN CN202180052278.1A patent/CN116528897A/zh active Pending
- 2021-08-26 EP EP21773945.7A patent/EP4204446A1/en active Pending
- 2021-08-26 AU AU2021332340A patent/AU2021332340A1/en active Pending
- 2021-08-26 IL IL300720A patent/IL300720A/en unknown
- 2021-08-26 WO PCT/US2021/047757 patent/WO2022047033A1/en not_active Ceased
- 2021-08-26 JP JP2023513355A patent/JP2023540037A/ja active Pending
- 2021-08-26 KR KR1020237009720A patent/KR20230058434A/ko active Pending
- 2021-08-26 CA CA3188716A patent/CA3188716A1/en active Pending
-
2023
- 2023-02-15 US US18/169,464 patent/US11987616B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023540037A5 (enExample) | ||
| JP2023534923A5 (enExample) | ||
| JP2023534922A5 (enExample) | ||
| US11987616B2 (en) | Antigen binding molecules targeting SARS-CoV-2 | |
| US11981725B2 (en) | Antigen binding molecules targeting SARS-CoV-2 | |
| US10016496B2 (en) | Respiratory syncytial virus F protein epitopes | |
| JP2011521662A5 (enExample) | ||
| US11248039B2 (en) | Immunoglobulin single variable domain antibody against RSV prefusion F protein | |
| WO2021212049A2 (en) | Anti-sars-cov-2 monoclonal antibodies | |
| WO2022083675A1 (zh) | 针对多种冠状病毒的单克隆抗体及应用 | |
| JP2023534922A (ja) | ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子 | |
| RS63580B1 (sr) | Humanizovana antitela protiv clever-1 i njihova primena | |
| JP2025537301A (ja) | Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子 | |
| ES2957464T3 (es) | Composiciones y métodos para tratar fibrosis pulmonar | |
| JP2025504537A (ja) | Ｈｂｖ感染及び関連疾患の治療のためのエピトープペプチド及び抗体 | |
| US20220340658A1 (en) | NEUTRALIZING ANTI-SARS-CoV-2 ANTIBODIES AND USE THEREOF | |
| CN110612310A (zh) | 抗cldn-5抗体及含有该抗体的药物 | |
| WO2022023292A2 (en) | Corona virus spike protein-targeting antibodies and use thereof | |
| Prasad et al. | Polybodies for the treatment of respiratory syncytial virus infection | |
| US20220289827A1 (en) | Neutralizing antibodies to sars-cov-2 and its variants | |
| US20260035436A1 (en) | Compositions and methods for directed ligand antibody development | |
| US20240043506A1 (en) | Sars-cov-2 antibodies | |
| CN119923414A (zh) | 溶酶体降解 | |
| CN116547005A (zh) | 靶向SARS-CoV-2的抗原结合分子 | |
| WO2025177283A1 (en) | Antibody-drug conjugates for targeting fibrosis |